Drug Profile


Alternative Names: ML 3000

Latest Information Update: 01 Nov 2007

Price : $50

At a glance

  • Originator EuroAlliance; Merckle
  • Developer EuroAlliance; Lacer
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antipyretics; Antirheumatics; Pyrroles; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Asthma; Inflammation; Osteoarthritis; Pain; Rheumatoid arthritis

Most Recent Events

  • 01 Nov 2007 This compound is still in active development
  • 13 Jul 2006 Discontinued - Preclinical for Rheumatoid arthritis in Europe (PO)
  • 13 Jul 2006 Discontinued - Phase-I for Pain in European Union (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top